Mnuchin told CNBC that he's confident President Donald Trump and President Xi Jinping can make progress in stalled trade talks.World Economyread more
U.S. stock index futures jumped Wednesday morning after Treasury Secretary Steven Mnuchin told CNBC that the U.S. and China were almost there on a trade deal.US Marketsread more
President Donald Trump's administration hopes additional sanctions on Iran will force the country to negotiate.Politicsread more
Democrats want Mueller's testimony on his probe into Russian interference in the 2016 election and Trump's efforts to influence it.Politicsread more
Stocks should rally if the U.S. and China agree to new negotiations and a ceasefire in the trade war, but the economic impact of tariffs will continue.Market Insiderread more
Bitcoin surged as high as $12,919 in early morning trade Wednesday, to its highest level since January 2018.Technologyread more
AbbVie's deal to buy Allergan for about $63 billion is a "nice exit from a tough situation," RBC Capital Markets analyst Randall Stanicky says.Biotech and Pharmaceuticalsread more
Omada Health just raised $73 million at a valuation of around $600 million as it seeks to expand its digital health offerings.Technologyread more
Chevy is just rolling out an all-new version of its heavy-duty Silverado with the new High Country trim package that could become the first U.S. pickup to top $100,000, Chevy...Autosread more
The trade war between Beijing and Washington appears to have depressed Chinese property purchases in the United States. China's own actions may also be playing a role.Real Estateread more
Tesla CEO Elon Musk sent out another email to his employees, pushing them to aim for a record number of vehicle deliveries to end the second quarter of 2019.Technologyread more
Losing exclusive contracts might normally seem like bad news, but shares of Quest Diagnostics and LabCorp surged on Friday after the rival lab services firms announced new non-exclusive agreements with health insurers.
Starting in 2019, LabCorp will no longer be the exclusive lab provider for UnitedHealth, but it will gain access to Aetna. Meanwhile, Quest will lose its exclusivity with Aetna, but will be among UnitedHealth's preferred providers.
Quest gained 4.9 percent on Friday, while LabCorp closed up 3.8 percent after hitting a historic high.
"This expanded agreement is the culmination of our years-long effort to return to a full collaborative relationship with Aetna," said LabCorp CEO David King in a statement announcing the new partnership. He said the company was also pleased with the term of its new agreement with United.
Analysts say the dual announcements mean Quest and LabCorp likely did not have to resort to rock-bottom pricing to hold onto their agreements, and likely won't suffer when it comes to market share.
"Quest and LabCorp are now de-risked from the possibility of getting denied access to a major health plan. While we view Quest as the net winner given it picks up more "net lives" … we believe both labs are well positioned to win back business from regional labs that had benefitted from (their past) exclusion from major health plan," wrote Canaccord Genuity analyst Mark Massaro in a note to clients.
For Quest, the new deal with UnitedHealth will give it access to United's 48 million members, which could well offset losing its exclusivity with Aetna's membership of 22 million.
"It expands our relationship with United which, I will share, is becoming more strategic for us," said Quest CEO Steve Rusckowski said in a phone interview. He added that it's also good for United members, "because those that have been using us as an out-of- network provider now will be in-network."
The new contract goes beyond lab services: It also includes more collaboration on diagnostic data and wellness services. That's an increasingly big focus for Quest – to leverage the company's own physical testing centers, and partnerships with retailers like Safeway and Walmart, to provide basic health services for consumers who may test positive for diabetes or high cholesterol.
"The opportunity, independent of the insurance companies … is to get great access for where we need to be to serve the population. And we continue to build on that network," Rusckowski explained.
The CEO added that focus on using its testing data for more consumer-focused services will position it well with increasingly new integrated health firms, such as the proposed CVS- Aetna and Cigna-Express Scripts mergers.
A few years ago, Quest and LabCorp came under pressure when would-be disruptor Theranos claimed it had developed a revolutionary machine that could provide test results from just one drop of blood. In March, the SEC charged Theranos' founder Elizabeth Holmes with what it called massive fraud.
When asked for his thoughts on the rise and fall of the start-up, Rusckowksi said there was one good thing that came out of the hype.
"It added a lot of visibility to our marketplace, a lot of attention placed on lab testing... and how the consumer should control it," he said. "It helped us to amplify what we're doing and now we're delivering on that promise."